Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment
Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.
You may also be interested in...
It’s decision time again at the European Medicines Agency and Roche’s Polivy is one of the new drug applications that is up for a potential marketing recommendation.
It's decision time again at the European Medicines Agency and Roche's Polivy and AstraZeneca's Qternmet are among the products up for an opinion on whether they should be approved in the EU.
Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.